The collaboration will give GSK access to Metabolon’s bioinformatics tools along with the company’s proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data. John Ryals, Metabolon President and CEO commented, “We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic ‘picture’ with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic and reduced risk and cost.”
Metabolon, Inc. has completed thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon’s technology platforms are robust and known for their rapid, repeatable results. Expert, credentialed biochemists interpret biological data to yield actionable insight into key disease metabolic processes, drug action, and patient response.